'Designer' drug shows activity in leukemia

December 09, 2002

PHILADELPHIA -- An experimental drug aimed precisely at a culprit genetic mutation has shown promising activity in a difficult-to-treat form of leukemia, say researchers from Dana-Farber Cancer Institute and their collaborators.

The scientists, who will present their findings at the annual meeting of the American Society of Hematology (ASH) in Philadelphia (Dec. 9, 11:15 a.m., Room 114), call the results a "proof of concept" even though none of the 15 patients treated with the drug, a Novartis Pharma compound known as PKC-412, went into remission. Thirteen of the patients did respond with reductions in their abnormally high white blood cell counts.

"This is really designer therapy" in that the drug is matched to a specific genetic flaw that distinguishes a particular form of acute myeloid leukemia (AML), says Dana-Farber's Richard Stone, MD, who will present the data at ASH.

The experimental compound is similar in concept to Gleevec, the first of the new "targeted" drugs that take advantage of an explosion of molecular information about cancer cells and their specific abnormalities. Because such drugs are aimed so narrowly, they are less likely to harm normal cells and tissues than conventional chemotherapy drugs with many and often severe side effects.

AML affects about 15,000 children and adults in the United States each year. In about one-third of patients, the cancerous blood cells contain an abnormal gene called FLT3, and those patients have a poorer prognosis than individuals who carry a normal FLT3 gene. The mutant gene transmits a signal that drives the cells into abnormal, excessive proliferation.

Previous work by James Griffin, MD, and Ellen Weisberg, PhD, of Dana-Farber, and Gary Gilliland, MD, PhD, of Brigham and Women's Hospital and Harvard Medical School, had shown that the experimental drug could block the harmful FLT3 growth signal in mice with a leukemia-like disease. The next question was whether it could do the same, and help patients, in a human clinical trial.

The 15 AML patients had either relapsed after treatment, achieved a temporary remission or had disease that was too stubborn to go into remission. They took the drug in pill form for up to 92 days. Nausea was the most common side effect, but otherwise the drug was well-tolerated, the researchers say.

In 13 of the patients, the drug caused abnormally high white cell counts to come down, dramatically in some cases. One patient had a count of 100,000 drop to normal (between 4,000 and 10,000) within a few days, Stone reports.

Although the drug didn't bring about a remission in any patient, "it's a lead," says Stone. "It is not a cure in itself, but combined with chemotherapy it might have a big impact." He says the trial will continue to enroll patients until 20 have undergone treatment with PKC-412. After that, the drug might be paired with a conventional chemotherapy drug to study the effect of the combination, says Stone.
Dana-Farber Cancer Institute (www.danafarber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.

Dana-Farber Cancer Institute

Related Chemotherapy Articles from Brightsurf:

Chemotherapy is used to treat less than 25% of people with localized sarcoma
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.

Starved cancer cells became more sensitive to chemotherapy
By preventing sugar uptake, researchers succeeded in increasing the cancer cells' sensitivity to chemotherapeutic treatment.

Vitamin D could help mitigate chemotherapy side effects
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.

Male fertility after chemotherapy: New questions raised
Professor Delb├Ęs, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.

'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.

Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.

Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.

Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.

A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.

Read More: Chemotherapy News and Chemotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.